Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05568680 · ClinicalTrials.gov registry record · Phase 1
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
A Phase 1 study of Ovarian Cancer and Mesothelioma, Malignant, sponsored by Verismo Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 4
- Study locations
NCT05568680 is a Phase 1 study of Ovarian Cancer and Mesothelioma, Malignant that is actively recruiting participants, run by Verismo Therapeutics. The registered enrollment target is 42 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05568680, a Phase 1 study of Ovarian Cancer and Mesothelioma, Malignant, is actively recruiting participants, sponsored by Verismo Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 4
- Study locations
Study Summary
This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.
Conditions Studied
Interventions
- BIOLOGICAL SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
Study Locations (4)
Kansas
- University of Kansas Cancer Center - Westwood
Pennsylvania
- University of Pennsylvania - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-03-30 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05568680
The ClinicalTrials.gov registry entry for NCT05568680 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Verismo Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR is the first listed.
NCT05568680 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Kansas, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT05568680 about?
NCT05568680 is a clinical study titled "SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma". This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.
What is the current status of trial NCT05568680?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2023-03-30. Estimated completion is 2027-12.
What conditions does trial NCT05568680 study?
This clinical trial studies the following conditions: Ovarian Cancer, Mesothelioma, Malignant, Cholangiocarcinoma Recurrent.
What interventions are being tested in trial NCT05568680?
The interventions under investigation include: SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR (BIOLOGICAL).
Who is sponsoring clinical trial NCT05568680?
This trial is sponsored by Verismo Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05568680 being conducted?
This trial has 4 study locations across Kansas, Pennsylvania, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.